What is the recommended treatment for a patient with decompensated cirrhosis, Child‑Pugh score 8 (Class B) and MELD score 14?

Treatment for Child-Pugh 8 (Class B), MELD 14 Decompensated Cirrhosis

For a patient with Child-Pugh score 8 (Class B) and MELD 14, immediately identify and aggressively treat the underlying etiology while simultaneously managing complications and considering liver transplant evaluation. 1

Primary Treatment Strategy: Etiology-Specific Intervention

The cornerstone of management is suppression of the causative factor, which remains the most effective approach even in decompensated disease 1:

By Etiology:

Hepatitis C:

• Initiate direct-acting antivirals (DAAs) immediately - specifically sofosbuvir combined with an NS5A inhibitor with or without ribavirin 2
• Your patient's MELD 14 places them at the threshold for increased decompensation risk during treatment 3
• Critical monitoring required: Albumin <3.5 g/dL, MELD >14, and HCV genotype 3 are independent risk factors for hepatic decompensation during DAA therapy 3
• Expected SVR rates exceed 80% even in decompensated patients 2
• Caution: Avoid protease inhibitor combinations despite efficacy due to safety concerns in decompensated patients 2

Hepatitis B:

• Start entecavir or tenofovir immediately - these are first-line due to potent HBV suppression and low resistance rates 4
• Child-Pugh B patients respond faster than Class C (mean 5.9 months vs 14 months to achieve 2-point CTP reduction) 5
• Earlier intervention in Class B yields superior clinical outcomes 5

Alcohol-related:

• Absolute alcohol cessation - though response is variable, some patients achieve progressive "re-compensation" with excellent long-term outcomes 1

Autoimmune hepatitis:

• Immunosuppression can reverse decompensation if disease activity is present, but avoid in "burn-out" cirrhosis 6

Secondary Management: Pathogenesis-Targeted Therapy

Non-Selective Beta-Blockers (NSBBs)

Initiate low-dose propranolol or carvedilol for this patient 7:

• With MELD ≤15, NSBBs reduce mortality by 28% (HR 0.72) 7
• Low-dose therapy shows mortality benefit (HR 0.74), while high-dose does not (HR 0.92) 7
• Benefits extend beyond variceal bleeding prevention to reducing ascites, hepatorenal syndrome, spontaneous bacterial peritonitis, and hepatic encephalopathy 1
• Critical caveat: Ensure adequate mean arterial pressure before initiation; benefit disappears with inconsistent baseline blood pressure 7

Additional Considerations:

Anticoagulation (if portal vein thrombosis present):

• Enoxaparin in Child-Pugh 7-10 delays decompensation and improves survival 1

Pentoxifylline:

• Reduces bacterial infections, renal failure, and hepatic encephalopathy by preventing bacterial translocation 1

Transplant Evaluation

Refer for liver transplant evaluation now - MELD 14 warrants listing consideration, though not urgent priority. This patient sits at a critical juncture where:

• Etiology-specific treatment may achieve clinical improvement
• Further decompensation could rapidly increase MELD score
• Early evaluation ensures readiness if disease progresses

Monitoring Protocol

Close surveillance is mandatory given MELD 14 status:

• Albumin levels (target >3.5 g/dL to reduce decompensation risk) 3
• Bilirubin (strongest predictor of treatment response) 8
• Renal function/eGFR 8
• Development of complications (ascites, encephalopathy, variceal bleeding, SBP)
• Hepatocellular carcinoma surveillance every 6 months

Critical Pitfalls to Avoid

1. Do not delay etiology-specific treatment - outcomes worsen with disease progression 1
2. Do not use high-dose NSBBs - mortality benefit only exists with low-dose therapy in this MELD range 7
3. Do not start DAAs without baseline albumin check - albumin <3.5 g/dL triples decompensation risk during treatment 3
4. Do not assume all patients improve with etiology treatment - results are "less efficacious" in decompensated vs compensated cirrhosis 1

Prognosis Context

With MELD 14 and Child-Pugh B, this patient has intermediate prognosis. Studies show only 7.6% of patients with MELD >15 achieve significant clinical improvement 8, placing your patient just below this threshold where intervention remains beneficial. The combination of etiology-specific therapy and complication management offers the best chance for stabilization or improvement before transplantation becomes necessary.